Profile data is unavailable for this security.
About the company
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
- Revenue in USD (TTM)0.00
- Net income in USD-96.49m
- Incorporated2015
- Employees59.00
- LocationInozyme Pharma Inc321 SUMMER STREET, SUITE 400BOSTON 02210United StatesUSA
- Phone+1 (857) 330-4340
- Fax+1 (302) 655-5049
- Websitehttps://www.inozyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2Seventy Bio Inc | 44.12m | -156.25m | 243.59m | 274.00 | -- | 1.04 | -- | 5.52 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.24m | 247.66m | 32.00 | -- | 1.70 | -- | 291.37 | -0.3573 | -0.3573 | 0.0064 | 1.06 | 0.0051 | -- | -- | 26,562.50 | -28.22 | -41.75 | -29.94 | -46.41 | -- | -- | -5,557.88 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Climb Bio Inc | 0.00 | -64.20m | 254.16m | 9.00 | -- | 1.14 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Omeros Corp | 0.00 | -199.92m | 255.55m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Editas Medicine Inc | 61.76m | -210.57m | 257.55m | 265.00 | -- | 1.47 | -- | 4.17 | -2.56 | -2.56 | 0.752 | 2.13 | 0.1484 | -- | 48.48 | 233,049.10 | -50.61 | -29.85 | -60.06 | -33.19 | -- | -- | -340.96 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Nektar Therapeutics | 93.16m | -177.08m | 257.71m | 137.00 | -- | 3.23 | -- | 2.77 | -0.9007 | -0.9007 | 0.4747 | 0.4329 | 0.2224 | 2.16 | 73.61 | 679,978.10 | -42.28 | -31.02 | -48.54 | -34.63 | 59.22 | 78.04 | -190.09 | -372.21 | 4.90 | -18.76 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Personalis Inc | 87.49m | -91.44m | 257.97m | 223.00 | -- | 1.93 | -- | 2.95 | -1.68 | -1.68 | 1.64 | 2.36 | 0.3751 | 7.18 | 6.45 | 392,327.30 | -39.20 | -28.84 | -45.99 | -34.72 | 31.41 | 28.65 | -104.52 | -96.01 | 4.44 | -- | 0.0098 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| Inozyme Pharma Inc | 0.00 | -96.49m | 258.25m | 59.00 | -- | 3.12 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Kodiak Sciences Inc | 0.00 | -197.68m | 258.86m | 111.00 | -- | 1.21 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Pyxis Oncology Inc | 16.15m | -59.20m | 262.65m | 51.00 | -- | 1.53 | -- | 16.27 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -77.22m | 264.49m | 58.00 | -- | 1.60 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Heron Therapeutics Inc | 136.36m | -48.13m | 265.42m | 126.00 | -- | -- | -- | 1.95 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Acrivon Therapeutics Inc | 0.00 | -69.00m | 265.43m | 58.00 | -- | 1.23 | -- | -- | -2.77 | -2.77 | 0.00 | 6.98 | 0.00 | -- | -- | 0.00 | -35.33 | -- | -37.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| MacroGenics Inc | 141.33m | -97.62m | 273.02m | 339.00 | -- | 2.27 | -- | 1.93 | -1.57 | -1.57 | 2.26 | 1.91 | 0.4676 | 3.24 | 8.30 | 416,899.70 | -32.30 | -37.76 | -39.53 | -45.53 | 95.07 | -- | -69.07 | -133.96 | 3.69 | -93.94 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
Data as of Nov 08 2024. Currency figures normalised to Inozyme Pharma Inc's reporting currency: US Dollar USD
49.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 30 Jun 2024 | 5.73m | 9.13% |
| Eventide Asset Management LLCas of 30 Jun 2024 | 3.94m | 6.27% |
| Rock Springs Capital Management LPas of 30 Jun 2024 | 3.70m | 5.90% |
| Samlyn Capital LLCas of 30 Jun 2024 | 3.35m | 5.34% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.04m | 4.85% |
| Affinity Asset Advisors LLCas of 30 Jun 2024 | 2.86m | 4.55% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.59m | 4.12% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 2.48m | 3.95% |
| Millennium Management LLCas of 30 Jun 2024 | 1.79m | 2.85% |
| Sphera Funds Management Ltd.as of 30 Jun 2024 | 1.46m | 2.33% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
